Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HM71224

- PMLiVE

Incyte announces agreement to acquire Escient Pharmaceuticals for $750m

The deal includes an MRGPRX2 antagonist with the potential to treat multiple mast cell-mediated diseases

- PMLiVE

Sobi shares positive phase 3 results for Doptelet in paediatric patients with rare blood disorder ITP

Immune thrombocytopenia is estimated to affect up to 100 people per million

- PMLiVE

Scleroderma Research Foundation launches clinical trial platform to advance treatments

The initiative will initially focus on interstitial lung disease secondary to scleroderma but will be expanded to address other manifestations of the disease

- PMLiVE

Lilly restructures in preparation for Alzheimer’s drug launch

As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration

- PMLiVE

Lilly restructures in preparation for Alzheimer’s drug launch

As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration

- PMLiVE

Amgen strikes $240m autoimmune deal with Evoq Therapeutics

Companies will collaborate on novel drugs for autoimmune disorders

- PMLiVE

Merck enters agreement with Hanmi for investigational NASH drug

Licensing agreement includes $10m upfront payment

- PMLiVE

Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs

The five-year deal includes Sitryx’ two lead projects

Eli Lilly HQ

Lilly, Pfizer say NGF drug works in back pain too

Tanezumab was able to show a statistically significant improvement in pain

- PMLiVE

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Insulin specialist bounces back with encouraging signs from Ozempic launch

Lilly appoints Maura Dickler as VP of late phase oncology development

She will join the pharma firm from the Memorial Sloan Kettering Cancer Center

Lilly bolsters its oncology team

Kimberly Blackwell is appointed VP early phase development, immuno-oncology

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links